Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

Completed · Phase 3 · Has a placebo group

Conditions studied: Parkinson's Disease

In brief

The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.

Key facts

Study ID

NCT00474058

Run by

UCB Pharma

People needed

287

Starts

2007-05-01

Expected to finish

2009-03-01

Last updated by the study team

2015-06-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Early and advanced Idiopathic Parkinson Disease with early morning motor impairment

You may not qualify if…

• Atypical Parkinsonian syndromes

Where it is running

• Study site — Berlin, Germany
• Study site — Berlin, Germany
• Study site — Dresden, Germany
• Study site — Kassel, Germany
• Study site — Leipzig, Germany
• Study site — Marburg, Germany
• Study site — Naumburg, Germany
• Study site — Ulm, Germany
• Study site — Budapest, Hungary
• Study site — Debrecen, Hungary
• Study site — Nyíregyháza, Hungary
• Study site — Zalaegerszeg, Hungary
• Study site — Chieti, Italy
• Study site — Milan, Italy
• Study site — Torino, Italy
• Study site — Christchurch, New Zealand
• Study site — Wellington, New Zealand
• Study site — Gdansk, Poland
• Study site — Krakow, Poland
• Study site — Lublin, Poland
• Study site — Olsztyn, Poland
• Study site — Szczecin, Poland
• Study site — Warsaw, Poland
• Study site — Cape Town, South Africa
• Study site — Capetown, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.